Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer

Carlo Barone, Maria DI Bartolomeo, Sara Lonardi, Evaristo Maiello, Erika Martinelli, Roberto Moretto, Antonia Strippoli, Emiliano Tamburini, Alberto Zaniboni, Carmine Pinto

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To help to remove misperception of an appropriate position of trifluridine/tipiracil (FTD/TPI) in the treatment of metastatic colorectal cancer. Materials & methods: The RAND Corporation/UCLA Appropriateness Method was used by a panel of Italian experts to develop recommendations concerning daily practice with FTD/TPI. Forty-three clinical scenarios were discussed in two rounds and the resulting statements were rated as appropriate, uncertain or inappropriate, according to the median score. Results: Several topics were dealt with, covering the profile of eligible patients, therapeutic options beyond the second line, the practice of treatment with FTD/TPI, evaluation and efficacy and toxicity, as well as costs and compliance. Conclusion: FTD/TPI is an important therapeutic resource in refractory metastatic colorectal cancer that combines manageability and safety.

Original languageEnglish
Pages (from-to)1749-1759
Number of pages11
JournalFuture Oncology
Volume17
Issue number14
DOIs
Publication statusPublished - May 2021

Keywords

  • metastatic colorectal cancer
  • RAND/UCLA Appropriateness Method
  • therapy beyond second line
  • trifluridine/tipiracil

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this